Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Blood (2016) 128 (22): 2992.

https://doi.org/10.1182/blood.V128.22.2992.2992

Published: 2016

Journal Articles

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Blood (2015) 126 (23): 2636.

https://doi.org/10.1182/blood.V126.23.2636.2636

Published: 2015

Journal Articles

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

Mitchell R. Smith, MD PhD, Hailun Li, PhD, Fangxin Hong, PhD, Leo I. Gordon, MD, Randy D. Gascoyne, Elisabeth Paietta, MD, Ranjana H Advani, MD, Andres Forrero-Torres, Sandra J Horning, MD, Brad S. Kahl, MD

Blood (2015) 126 (23): 2702.

https://doi.org/10.1182/blood.V126.23.2702.2702

Published: 2015

Journal Articles

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

Julie E. Chang, Hailun Li, Mitchell R. Smith, Randy D. Gascoyne, Elisabeth M. Paietta, David T. Yang, Ranjana H. Advani, Sandra J. Horning, Brad S. Kahl

Blood (2014) 123 (11): 1665–1673.

https://doi.org/10.1182/blood-2013-08-523845

Published: 2014

Includes: Supplemental data

Journal Articles

Improved Risk Stratification With Addition Of Male Sex (S) To The Elderly International Prognostic Index (S-EIPI) For DLBCL Patients > 60 Years Treated With R-CHOP: An International Collaboration Of The US Intergroup, German High-Grade Non-Hodgkin Lymphoma Study Group and Groupe d’Etude De Lymphome d’Adultes

Ranjana H. Advani, MD, Fangxin Hong, PhD, Thomas M. Habermann, MD, Hailun Li, MS, Brad S. Kahl, MD, Vicki A. Morrison, MD, Edie A. Weller, PhD, Gaurav Varma, MSPH, Richard I Fisher, MD, Bruce A. Peterson, MD, Bruce D. Cheson, M.D., Randy D. Gascoyne, MD, Sandra J. Horning, MD, Sami Bousetta, Bertrand Coiffier, MD, PhD, Marita Ziepert, Michael Pfreundschuh, MD

Blood (2013) 122 (21): 3045.

https://doi.org/10.1182/blood.V122.21.3045.3045

Published: 2013

Journal Articles

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

Fangxin Hong, Ph.D., Thomas M Habermann, MD, Leo I. Gordon, MD, Howard S Hochster, MD, Randy D. Gascoyne, MD, Vicki A. Morrison, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Patrick J Stiff, MD, Bruce D. Cheson, M.D., Michael Crump, MD FRCPC, Sandra J. Horning, MD, Brad S. Kahl, MD

Blood (2013) 122 (21): 3060.

https://doi.org/10.1182/blood.V122.21.3060.3060

Published: 2013

Journal Articles

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Blood (2013) 122 (21): 4277.

https://doi.org/10.1182/blood.V122.21.4277.4277

Published: 2013

Journal Articles

Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma

Jennifer A. Kanakry, Meir Shamay, Yvette L. Kasamon, Hailun Li, MS, Randy D. Gascoyne, MD, Leo I. Gordon, MD, Ariela Noy, MD, Ethel Cesarman, MD, PhD, Jeannette Y Lee, Ph.D., Sandra J. Horning, MD, Richard F. Ambinder

Blood (2013) 122 (21): 4232.

https://doi.org/10.1182/blood.V122.21.4232.4232

Published: 2013

Journal Articles

Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma

Bartosz Grzywacz, MD, Amy K Erbe, PhD, Wei Wang, BS, Erik A. Ranheim, MD, PhD, Jacquelyn A Hank, PhD, KyungMann Kim, PhD, Lakeesha Carmichael, MS, Songwon Seo, MS, Eneida A Mendonca, MD, PhD, Yiqiang Song, MS, Fangxin Hong, PhD, Randy D. Gascoyne, MD, Elisabeth Paietta, PhD, Sandra J. Horning, MD, Brad S. Kahl, MD, Paul M Sondel, MD, PhD

Blood (2013) 122 (21): 507.

https://doi.org/10.1182/blood.V122.21.507.507

Published: 2013

Journal Articles

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Daryl Tan, Sandra J. Horning, Richard T. Hoppe, Ronald Levy, Saul A. Rosenberg, Bronislava M. Sigal, Roger A. Warnke, Yasodha Natkunam, Summer S. Han, Alan Yuen, Sylvia K. Plevritis, Ranjana H. Advani

Blood (2013) 122 (6): 981–987.

https://doi.org/10.1182/blood-2013-03-491514

Published: 2013

Includes: Supplemental data

Journal Articles

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Jennifer A. Kanakry, Hailun Li, Lan L. Gellert, M. Victor Lemas, Wen-son Hsieh, Fangxin Hong, King L. Tan, Randy D. Gascoyne, Leo I. Gordon, Richard I. Fisher, Nancy L. Bartlett, Patrick Stiff, Bruce D. Cheson, Ranjana Advani, Thomas P. Miller, Brad S. Kahl, Sandra J. Horning, Richard F. Ambinder

Blood (2013) 121 (18): 3547–3553.

https://doi.org/10.1182/blood-2012-09-454694

Published: 2013

Includes: Supplemental data

Journal Articles

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Ranjana H. Advani, MD, Hailun Li, MS, Richard T. Hoppe, MD, Nancy L. Bartlett, MD, John M. Bennett, MD, Donna S. Neuberg, ScD, Peter A Cassileth, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 4779.

https://doi.org/10.1182/blood.V120.21.4779.4779

Published: 2012

Journal Articles

Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Brad S. Kahl, M.D., Hailun Li, MS, Mitchell R Smith, MD, PhD, Randy D. Gascoyne, MD, David T. Yang, MD, Elisabeth Paietta, PhD, Ranjana H. Advani, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 153.

https://doi.org/10.1182/blood.V120.21.153.153

Published: 2012

Journal Articles

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Blood (2012) 120 (21): 3701.

https://doi.org/10.1182/blood.V120.21.3701.3701

Published: 2012

Journal Articles

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

Thomas M Habermann, MD, Fangxin Hong, PhD, Vicki A. Morrison, MD, Shaker R. Dakhil, MD, James K. Weick, MD, Stanley R. Frankel, MD, Randy D. Gascoyne, MD, Richard I Fisher, MD, Bruce D. Cheson, MD, Edie A. Weller, PhD, Brad S. Kahl, M.D., Bruce A. Peterson, MD, Howard S Hochster, MD, Sandra J. Horning, M.D.

Blood (2012) 120 (21): 3705.

https://doi.org/10.1182/blood.V120.21.3705.3705

Published: 2012

Journal Articles

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Thomas E. Witzig, MD, Fangxin Hong, Ph.D., Ivana N. Micallef, MD, Randy D. Gascoyne, MD, Ahmet Dogan, MD, PhD, Henry Wagner, Jr., MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 2687.

https://doi.org/10.1182/blood.V120.21.2687.2687

Published: 2012

Journal Articles

Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

Lynne I. Wagner, Ph.D., Fengmin Zhao, Ph.D., Michael E. Williams, M.D., Randy D. Gascoyne, MD, John C. Krauss, M.D., David Cella, Ph.D., Sandra J. Horning, M.D., Brad S. Kahl, M.D.

Blood (2012) 120 (21): 235.

https://doi.org/10.1182/blood.V120.21.235.235

Published: 2012

Journal Articles

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Lode J. Swinnen, Hailun Li, MS, Andrew Quon, MD, Randy D. Gascoyne, MD, Erik A. Ranheim, MD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Brad S. Kahl, M.D., Sandra J. Horning, M.D.

Blood (2012) 120 (21): 687.

https://doi.org/10.1182/blood.V120.21.687.687

Published: 2012

Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Blood (2012) 120 (21): 548.

https://doi.org/10.1182/blood.V120.21.548.548

Published: 2012

Journal Articles

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

King L. Tan, David W. Scott, Fangxin Hong, Brad S. Kahl, Richard I. Fisher, Nancy L. Bartlett, Ranjana H. Advani, Rena Buckstein, Lisa M. Rimsza, Joseph M. Connors, Christian Steidl, Leo I. Gordon, Sandra J. Horning, Randy D. Gascoyne

Blood (2012) 120 (16): 3280–3287.

https://doi.org/10.1182/blood-2012-04-421057

Published: 2012

Includes: Supplemental data

NARROW

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Initial Therapy for Mantle Cell Lymphoma with Abbreviated R-CHOP Followed By Y 90 -Ibritumomab Tiuxetan: Ten Year Follow-up of the Phase 2 ECOG-ACRIN Study E1499

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience

Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496

Characterizing The CpG Methylation Of Epstein-Barr Virus DNA In The Plasma Of Patients With Hodgkin Lymphoma and HIV-Associated Burkitt Lymphoma

Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years

Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma

Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant

Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab

A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).

Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only